Bimagrumab for adults with heart failure with preserved ejection fraction
Tests bimagrumab in adults whose heart pumps normally but fills poorly.
Plain-language title generated from the registry record
Registry title: A Study of Bimagrumab in Participants With HFpEF
Key facts
- Where
- Krakow and Wroclaw, PolandSee the 3 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a type of heart failure called HFpEF, where the heart pumps normally but does not fill well. It tests bimagrumab against placebo.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Heart failure NYHA class II to III. Left ventricular ejection fraction (LVEF) of 50% or more. KCCQ-CSS of 80 or less. 6-minute walk distance of 100 to 450 meters. Body mass index (BMI) of 23 kg/m² or more. Needs at least one sign: a heart failure event, high NT-proBNP, an enlarged left atrium, or high filling pressure.
- Earlier treatment
- Must be on a stable dose of heart failure medications.
- Biomarker or test result
- Elevated NT-proBNP is one of the accepted signs, together with the other signs listed.
Main reasons for not taking part
- Hospitalised for heart failure less than 4 weeks before screening
- Heart attack, bypass or other major heart surgery, stroke or TIA in the 12 weeks before screening
- Unstable angina in the 4 weeks before screening or during screening
- Type 1 diabetes
- Hemoglobin A1c (HbA1c) of 9.5% (80 mmol/mol) or more
Read by machine on 13 November 2026.
Where in Poland
- Krakowski Szpital Specjalistyczny im sw.Jana Pawla IIKrakow, PolandContact: Pawel Rubis (principal investigator)No longer taking part
- 4 Wojskowy Szpital Kliniczny z Poliklinika Samodzielny Publiczny ZOZ we WroclawiuWroclaw, PolandContact: Bartosz Krakowiak (principal investigator)No longer taking part
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandContact: Joanna Szachniewicz (principal investigator)No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07920887EU 2026-527983-34-00
- Record updated
- 6 November 2026
- Original description
This study will look at how bimagrumab affects adults who have a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart pumps normally but does not fill with blood as well as it should. Participation in the study will last about 76 weeks.Read full original descriptionShow less
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing the Efficacy and Safety of Bimagrumab Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction (ACTIVATE-HFpEF)
This study will look at how bimagrumab affects adults who have a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart pumps normally but does not fill with blood as well as it should. Participation in the study will last about 76 weeks.
Inclusion: Have New York Heart Association Class II to III heart failure; Have left ventricular ejection fraction (LVEF) ≥ 50%; KCCQ-CSS ≤ 80; 6MWD must be all of the following:; ≥100 and ≤ 450 meters (m) based on average of 2 tests conducted at screening visit, AND; ≥ 100 and ≤ 450 m on 1 test at randomization visit, AND; < 20% change from average qualifying 6MWD obtained at screening; Have documented evidence of at least one of the following:; Heart failure event; Elevated NT-proBNP (N-terminal pro B-type natriuretic peptide); Left atrium enlargement; Elevated filling pressure; Stable dose of heart failure medications; Body mass index (BMI) ≥ 23 kilograms per meter squared (kg/m²).
Exclusion: Heart failure hospitalization < 4 weeks before screening; Myocardial infarction, coronary artery bypass graft surgery, or other major cardiovascular surgery/intervention, stroke or transient ischemic attack in past 12 weeks prior to screening, or unstable angina pectoris in past 4 weeks prior to screening or during screening; Type 1 diabetes; Hemoglobin A1c (HbA1c) ≥ 9.5%.